Table 4.
Oncolytic virus in combination with ICBs
| Oncolytic virus | ICB | Cancer type | Trial NO | Phase | Status | Refs. |
|---|---|---|---|---|---|---|
| HSV 1 | ||||||
| T-VEC | Atezolizumab | Early Breast Cancer | NCT03802604 | 1 | Recruiting | |
| Atezolizumab | Triple-Negative Breast Cancer and Colorectal Cancer With Liver Metastases | NCT03256344 | 1 | Active, not recruiting | ||
| Pembrolizumab | Recurrent Metastatic HNSCC | NCT02626000 | 1 | Completed | [156] | |
| Ipilimumab | Unresected Melanoma | NCT01740297 | 1/2 | Completed | [153] | |
| Pembrolizumab | Liver Tumors | NCT02509507 | 1/2 | Active, not recruiting | ||
| Nivolumab and Ipilimumab | Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | NCT04185311 | 1 | Active, not recruiting | ||
| Nivolumab | Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | NCT02978625 | 2 | Recruiting | ||
| Pembrolizumab | Metastatic and/or Locally Advanced Sarcoma | NCT03069378 | 2 | Recruiting | ||
| Pembrolizumab | Stage III-IV Melanoma | NCT02965716 | 2 | Active, not recruiting | ||
| Pembrolizumab | Stage III Melanoma | NCT03842943 | 2 | Recruiting | ||
| Pembrolizumab | Unresectable/Metastatic Melanoma | NCT04068181 | 2 | Active, not recruiting | ||
| Pembrolizumab | Unresected Melanoma | NCT02263508 | 3 | Terminated | [155] | |
| HF10 | Ipilimumab | Unresectable or Metastatic Melanoma | NCT02272855 | 2 | Completed | [158] |
| Ipilimumab | Unresectable or Metastatic Melanoma | NCT03153085 | 2 | Completed | [159] | |
| T3011 (Intratumoral) | Pembrolizumab | Advanced or Metastatic Solid Tumors | NCT04370587 | 1/2 | Recruiting | |
| T3011 (Intravenous) | Pembrolizumab | Advanced or Metastatic Solid Tumors | NCT04780217 | 1/2 | Recruiting | |
| ONCR-177 | Pembrolizumab | Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | NCT04348916 | 1 | Recruiting | |
| RP1 | Cemiplimab | Advanced Squamous Skin Cancer | NCT04050436 | 2 | Recruiting | |
| Nivolumab | Advanced and/or Refractory Solid Tumors | NCT03767348 | 2 | Recruiting | ||
| Ad | ||||||
| ONCOS-102 | Pembrolizumab | Advanced or Unresectable Melanoma Progressing After PD-1 Blockade | NCT03003676 | 1 | Completed | [161] |
| Durvalumab | Advanced Peritoneal Malignancies | NCT02963831 | 1/2 | Active, not recruiting | ||
| LOAd703 | Atezolizumab | Pancreatic Cancer | NCT02705196 | 1/2 | Recruiting | |
| Malignant Melanoma | NCT04123470 | 1/2 | Recruiting | |||
| Adenovirus CCL21 | Pembrolizumab | Stage IV NSCLC | NCT03546361 | 1 | Recruiting | |
| NG-641 | Nivolumab | Metastatic or Advanced Epithelial Tumors | NCT05043714 | 1 | Not yet recruiting | |
| ADV/HSV-tk | Pembrolizumab | Metastatic NSCLC, Metastatic Triple-negative Breast Cancer | NCT03004183 | 2 | Active, not recruiting | |
| ChAdOx1-MVA 5T4 | Nivolumab | Advanced Prostate Cancer | NCT03815942 | 1/2 | Active, not recruiting | |
| DNX-2401 | Pembrolizumab | Recurrent Glioblastoma or Gliosarcoma | NCT02798406 | 2 | Completed | |
| VB-111 | Nivolumab | Metastatic Colorectal Cancer | NCT04166383 | 2 | Recruiting | |
| Adenoviral-mediated IL-12 | Pembrolizumab | Triple-Negative Breast Cancer | NCT04095689 | 2 | Recruiting | |
| VCN-01 | Durvalumab | HNSCC | NCT03799744 | 1 | Recruiting | |
| SynOV1.1 | Atezolizumab | Hepatocellular Carcinoma | NCT04612504 | 1/2 | Not yet recruiting | |
| OBP-301 | Pembrolizumab | HNSCC With Inoperable Recurrent or Progressive Disease | NCT04685499 | 2 | Recruiting | |
| VV | ||||||
| TBio-6517 | Pembrolizumab | Advanced Solid Tumors | NCT04301011 | 1/2 | Recruiting | |
| P53MVA | Pembrolizumab | Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03113487 | 2 | Recruiting | |
| Pembrolizumab | Solid Tumors That Have Failed Prior Therapy | NCT02432963 | 1 | Active, not recruiting | ||
| Pexa-Vec (JX-594) | Durvalumab and Tremelimumab | Refractory Colorectal Cancer | NCT03206073 | 1/2 | Active, not recruiting | |
| Ipilimumab | Metastatic / Advanced Solid Tumors | NCT02977156 | 1 | Recruiting | ||
| Cemiplimab | Renal Cell Carcinoma | NCT03294083 | 1/2 | Recruiting | ||
| BT-001 | Pembrolizumab | Metastatic or Advanced Solid Tumors | NCT04725331 | 1/2 | Recruiting | |
| PROSTVAC | Nivolumab | Prostate Cancer | NCT02933255 | 1/2 | Recruiting | |
| Nivolumab and Ipilimumab | Metastatic Hormone-Sensitive Prostate Cancer | NCT03532217 | 1 | Active, not recruiting | ||
| CV301 | Nivolumab | Metastatic Colorectal Cancer | NCT03547999 | 2 | Active, not recruiting | |
| TG4010 | Nivolumab | NSCLC | NCT02823990 | 2 | Active, not recruiting | |
| Coxsackievirus | ||||||
| CVA21 | Ipilimumab | Advanced Melanoma | NCT02307149 | 1 | Completed | [162] |
| Pembrolizumab | Advanced Melanoma | NCT02565992 | 1 | Completed | [163] | |
| Ipilimumab | Uveal Melanoma Metastatic to the Liver | NCT03408587 | 1 | Completed | ||
| Pembrolizumab | NSCLC and Bladder Cancer | NCT02043665 | 1 | Completed | ||
| Pembrolizumab | Advanced/Metastatic Solid Tumors | NCT04521621 | 1/2 | Recruiting | ||
| Pembrolizumab | Stage III Melanoma | NCT04303169 | 1/2 | Recruiting | ||
| Pembrolizumab | Advanced/Metastatic Melanoma | NCT04152863 | 2 | Recruiting | ||
| Polio/rhinovirus | ||||||
| PVSRIPO | PD-1 mAb | Advanced PD-1 Refractory Melanoma | NCT04577807 | 2 | Recruiting | |
| PD-1/L1 mAb | Advanced Solid Tumors | NCT04690699 | 1/2 | Recruiting | ||
| Pembrolizumab | Recurrent Glioblastoma | NCT04479241 | 2 | Recruiting | ||
| MRB | ||||||
| MG1-MAGEA3 and Ad-MAGEA3 | Pembrolizumab | NSCLC | NCT02879760 | 1/2 | Completed | |
| MG1-E6E7 and Ad-E6E7 | Atezolizumab | HPV Associated Cancers | NCT03618953 | 1 | Active, not recruiting | |
| VSV | ||||||
| VSV-IFNβ-NIS | Pembrolizumab | NSCLC and HNSCC | NCT03647163 | 1/2 | Recruiting | |
| Avelumab | Malignant Solid Tumor | NCT02923466 | 1 | Active, not recruiting | ||
| Reovirus | ||||||
| Pelareorep | Nivolumab | Relapsed/Refractory Multiple Myeloma | NCT03605719 | 1 | Recruiting | |
| Atezolizumab | Early Breast Cancer | NCT04102618 | 1 | Recruiting | ||
| Avelumab | Metastatic Breast Cancer | NCT04215146 | 2 | Recruiting | ||
| NDV | ||||||
| MEDI9253 | Durvalumab | Solid Tumors | NCT04613492 | 1 | Recruiting | |
| HSV 2 | ||||||
| OH2 | Pembrolizumab | Advanced Solid Tumors | NCT04386967 | 1/2 | Recruiting | |